Spoon Feed
Molnupiravir is an oral antiviral drug that has been shown to decrease risk of hospitalization or death at 29 days in patients with mild to moderate COVID-19 who are at risk for progression to severe disease
Spoon Feed
New research on droperidol shows that it is a safe and effective medication for a multitude of common ED presentations, despite an FDA black box warning for QTc prolongation in 2001.
Spoon Feed
J-Tip lidocaine infusion did not reduce first-attempt IV success and reduced pain compared to no local anesthetic in children.
Spoon Feed
Outpatient IV remdesivir was effective in reducing COVID-related hospitalization in high risk outpatients.
Spoon Feed
In patients with moderate renal dysfunction (eGFR 15-59 mL/min/m2), giving 10 units vs 5 units of IV insulin for hyperkalemia did not result in a statistically significant difference in rates of hypoglycemia. Administering 10 units was shown to lower serum K by ~0.3 mmol/L more than 5 units.
Spoon Feed
Apixaban and rivaroxaban are two of the most prescribed direct oral anticoagulants (DOACs), but there are limited head-to-head comparisons of the medications. This study finds apixaban is associated with lower rates of VTE recurrence, GI Â bleeds and ICH compared to rivaroxaban.
Spoon Feed
Given the negligible downsides of TXA and the known harms of packing, it’s worth a try in our patients with epistaxis.
Spoon Feed
TXA is a safe and effective topical treatment for epistaxis, with 3.5 times greater odds of bleeding cessation at first reassessment compared to placebo, lidocaine plus vasoconstrictors, or local anesthetics.
Spoon Feed
A composite outcome encompassing both clinical response and adverse effects of antibiotics was superior in children who received 5 vs 10 days of antibiotics for pediatric community acquired pneumonia.
Spoon Feed
IV magnesium (IV-Mg) was associated with worsening asthma score in children, greater odds of hospitalization, and no acceleration of exacerbation resolution in hospitalized patients.
